One of the most promising drugs for Alzheimer's disease fails in clinical trials

Los Angeles Times – To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer’s disease and come up short, we can now add three more.

An experimental drug called idalopirdine failed to help people with mild to moderate Alzheimer’s disease in a trio of trials that involved 2,525 patients in 34 countries. Not only did the drug fail to bring about any meaningful change in cognitive tests that are widely used in diagnosing and tracking the progress of the disease, it also failed to cause significant improvements in general measures of daily function among those taking it at any of three tested doses.

Those are relatively modest goals — not to reverse Alzheimer’s disease or block its progress, but simply to slow the loss of function in those who have it. Even that, it turns out, is a humbling challenge.

The failure of idalopirdine, reported Tuesday in the Journal of the American Medical Assn., probably marks the unraveling of an approach to Alzheimer’s treatment that has long looked promising.

Read more at Los Angeles Times.

News Image
An old woman looking away from camera
Topics
Neuroscience
Action
Industry Science